For the more than 1 million Americans who live with type 1 diabetes, daily insulin injections are literally a matter of life and death. And while there is no cure, a Cornell-led research team has developed a device that could revolutionize management of the disease.
In Type 1 diabetes, insulin-producing pancreatic cell clusters (islets) are destroyed by the body’s immune system. The research group, led by assistant professor Minglin Ma from the Department of Biological and Environmental Engineering in the College of Agriculture and Life Sciences, has devised an ingenious method for implanting hundreds of thousands of islet cells into a patient. They are protected by a thin hydrogel coating and, more importantly, the coated cells are attached to a polymer thread and can be removed or replaced easily when they have outlived their usefulness.
Doctoral students Duo An and Alan Chiu are co-lead authors of the group’s paper, “Designing a Retrievable and Scalable Cell Encapsulation Device for Potential Treatment of Type 1 Diabetes,” published Dec. 25 in Proceedings of the National Academy of Sciences.
An example of the “radical collaboration” concept that is a hallmark of Cornell research, this work also featured key contributions from: Dr. James Flanders from the College of Veterinary Medicine; professor Jintu Fan from the Department of Fiber Science & Apparel Design in the College of Human Ecology; and assistant professor Meredith Silberstein from the Department of Mechanical and Aerospace Engineering in the College of Engineering.
Transplantation of stem cell-derived, insulin-producing islet cells is an alternative to insulin therapy, but that requires long-term immunosuppressive drug administration. One well-researched approach to avoid the immune system’s response is to coat and protect the cells in tiny hydrogel capsules, hundreds of microns in diameter. However, these capsules cannot be taken out of the body easily, since they’re not connected to each other, and there are hundreds of thousands of them.
And the ability to remove the transplant is key because of the potential of tumors forming when stem cell-derived, insulin-producing cells – the most promising cell source for type 1 diabetes cell therapies – are used.
“When they fail or die, they need to come out,” Ma said. “You don’t want to put something in the body that you can’t take out. With our method, that’s not a problem.”
Taking inspiration from the way water beads on a spider’s web, Ma and his team first attempted to connect the islet cell-containing capsules through a string but realized that it would be better to put the hydrogel layer uniformly around a string instead.
That string: an ionized calcium-releasing, nanoporous polymer thread. The device starts with two sterile nylon sutures twisted in a helix, then folded over to facilitate the subsequent nanoporous structure coatings. Placed onto that thread is a thin layer of islet cell-containing alginate hydrogel, which adheres to the helical, nanoporous thread, similar to dew drops sticking to the spider silk. Alginate is a seaweed extract commonly used in encapsulated cell transplantation.
This thread – which the group has dubbed TRAFFIC (Thread-Reinforced Alginate Fiber For Islets enCapsulation) – was inspired by a spider’s web but, according to Ma, is even better because the hydrogel covers the thread uniformly.
“You don’t have any gaps between capsules,” he said. “With a spider’s silk, you still have gaps between the water beads. In our case, gaps would be bad in terms of scar tissue and the like.”
And since the thread is twisted and porous, the hydrogel won’t slip off as it would on a single, smooth piece of material. Fan and Silberstein were instrumental in modeling different options for the thread configuration.
This therapy would involve minimally invasive laparoscopic surgery to implant approximately six feet of hydrogel-coated thread into the patient’s peritoneal cavity.
“We only need two quarter-inch-long incisions,” Flanders said. “We inflate the abdomen with carbon dioxide, which gives us room to work, and then put in two ports – one for a scope that’s hooked to a camera, so we can see what we’re doing, and the other for a grasping device, which is how we introduce the implant.”
TRAFFIC’s large surface area promotes better mass transfer, Ma said, and diffusion is good because all the islet cells are near the surface. Current life span estimates for the thread are between six and 24 months, although more testing is necessary.
In mice, blood glucose levels were returned to normal two days after implantation of a one-inch length of TRAFFIC, and remained normal for at least three months when the experiment ended. Retrievability was tested in multiple dogs, with 10-inch samples being successfully implanted and removed laparoscopically.
Flanders, who performed surgical implantation in canines, said among the different dogs and devices tested there was either no or only minimal adhesion of the device to surrounding tissue upon removal.
This collaboration has produced a potentially game-changing medical device, he said.
“When Minglin first told me about this, I thought it was brilliant,” Flanders said. “There have been other devices sort of like this, but this one seems to have so much promise. It’s minimally reactive, it protects the islet cells, it allows them to sense glucose, they don’t attach to anything, and it can be easily removed. To me, it sounded like a win-win.”
Learn more: Removable implant may control type 1 diabetes
The Latest on: Type 1 diabetes
- Biomarker identified for early beta cell death in type 1 diabeteson September 6, 2019 at 6:43 am
Beta cells in the pancreas produce insulin. Their death is a key feature of Type 1 diabetes, and that loss starts long before diagnosis. However, there has been no straightforward way to measure ...
- Fiduciary Trust Sponsors JDRF Greater Bay Area Chapter’s Annual Meeting, Supports Organization’s Research to Fight and Treat Type 1 Diabeteson September 5, 2019 at 9:00 am
SAN FRANCISCO, Sept. 05, 2019 (GLOBE NEWSWIRE) -- Fiduciary Trust Company International, a global wealth manager and wholly-owned subsidiary of Franklin Templeton, is proud to partner with JDRF, a ...
- JDRF Launches Northern California Center Of Excellence To Accelerate Breakthroughs To Cure Type 1 Diabeteson September 4, 2019 at 5:07 pm
NEW YORK, Sept. 4, 2019 /PRNewswire/ -- JDRF, the leading global organization funding type 1 diabetes (T1D) research, today announced the launch of the JDRF Northern California Center of ...
- Vertex Pharmaceuticals' $950 Million Bet on Curing Type 1 Diabetes Could Have an Astronomical Payoffon September 4, 2019 at 2:11 pm
Vertex Pharmaceuticals (NASDAQ: VRTX) holds a virtual monopoly in treating cystic fibrosis (CF). But the successful biotech isn't content with winning in only one therapeutic area. Vertex is also ...
- Vertex buys developer of preclinical cell therapy for Type 1 diabetes for $950Mon September 3, 2019 at 11:50 am
Vertex Pharmaceuticals is betting nearly $1 billion on a company developing a stem cell-based therapy and device with the stated goal of creating a potentially curative treatment for Type 1 ...
- Vertex’s next act: a billion-dollar bet on a cure for type 1 diabeteson September 3, 2019 at 6:10 am
Vertex Pharmaceuticals announced Tuesday that it plans to acquire an ambitious startup for $950 million, betting the company’s early-stage science could lead to a functional cure for type 1 diabetes.
- Vertex to Acquire Semma Therapeutics With a Goal of Developing Curative Cell-Based Treatments for Type 1 Diabeteson September 3, 2019 at 5:00 am
Vertex Pharmaceuticals Incorporated VRTX, +0.58% today announced that the company has entered into a definitive agreement under which Vertex will acquire Semma Therapeutics, a privately held ...
- Discovery may help identify signs of type 1 diabetes earlieron September 2, 2019 at 7:20 pm
A new study showed that there are significant differences in the MHC class II antigens on the insulin peptide that is deficient in type 1 diabetes mellitus (T1DM). These determine the response of the ...
- New discovery may help identify type 1 diabetes earlier than is currently possibleon August 30, 2019 at 1:58 pm
Type 1 diabetes, an autoimmune disease that typically emerges before the age of 20, wipes out the body's ability to produce insulin--a hormone that's essential to life. Diagnosis often comes after ...
- Health Beat: Type 2 drugs: Life-changing for Type 1 diabeteson August 27, 2019 at 12:18 pm
ST. LOUIS - As president of a car dealership, Eric Rehkemper is a busy man. He stays cool under pressure, all while managing Type 1 diabetes. "It's a 24/7, seven days a week, whether you're on ...
via Google News and Bing News